（来源：中华工商时报） 转自：中华工商时报 在民企路演环节，广州力多机器人智能科技集团有限公司、广东钰顺数字科技有限公司携定制化方案亮 相，展现民营经济在细分领域的技术积淀与场景落地能力。广州力多机器人围绕超高层建筑造楼机安全 性能提升需求，分享其自主研发真空负压攀爬机器人的技术优势、安全保障及成本控制方案。广东钰顺 数科紧扣国企人力资源数字化转型需求，以全生命周期数字化解决方案、AI技术应用及标杆项目实践 为核心展开路演，提供成熟破解路径。两家企业的精准回应，诠释了"国企搭骨架、民企填血肉"的产业 生态理念，获得现场国企代表广泛认可。 自由对接环节，国企与民企代表围绕项目细节深入洽谈，凝聚合作共识。多位国企、民企代表表示，活 动为双方搭建了直达高效的交流平台，有效助力双方深度融合、共赢发展。主办方明确，将以此次活动 为契机，健全"需求发布-精准匹配-项目落地-跟踪服务"长效机制，推动"对接清单"转化为"成果清单"， 确保国企民企合作"不断线、能深化、见实效"。 此次活动既是国企民企精准对接、携手攻坚的实效平台，更是国有经济与民营经济双向赋能、共生共荣 的生动实践。通过"揭榜挂帅"模式，有效打通了国企资源优势 ...

Group 1 - The event "Unveiling the Banner and Leading the Energy, National Integration Starts a New Journey" was co-hosted by the Guangzhou Federation of Industry and Commerce and the Guangzhou State-owned Assets Supervision and Administration Commission, aimed at creating an efficient platform for cooperation between state-owned enterprises (SOEs) and private enterprises (PEs) [1][4] - The event focused on 12 "unveiling" demand projects from 10 key SOEs, aligning with the cooperation intentions of PEs, facilitating close communication between supply and demand sides [3][4] - Five key SOEs, including Guangzhou Pharmaceutical Group and Guangzhou Construction Group, presented specific demands in fields such as biomedicine, high-end equipment manufacturing, and artificial intelligence, while the remaining SOEs engaged in precise matching through on-site discussions [3][4] Group 2 - The private enterprise roadshow highlighted innovative companies like Guangzhou Lido Robot Intelligent Technology Group and Guangdong Yushun Digital Technology, showcasing their customized solutions and technical capabilities in niche areas [3] - Guangzhou Lido Robot presented its self-developed vacuum negative pressure climbing robot, emphasizing safety performance improvements and cost control solutions for high-rise building construction [3] - Guangdong Yushun Digital Technology focused on digital transformation needs of SOEs, offering comprehensive digital solutions and AI technology applications, which received broad recognition from SOE representatives [3][4] Group 3 - The event facilitated in-depth discussions between SOE and PE representatives, fostering a consensus on cooperation and creating a direct and efficient communication platform [4] - The organizers plan to establish a long-term mechanism for "demand release - precise matching - project implementation - follow-up service" to ensure continuous and effective cooperation between SOEs and PEs [4]

Group 1 - LSV Asset Management increased its stake in Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (00874.HK) by purchasing 118,000 shares at an average price of HKD 18.7863 per share, totaling approximately HKD 2.2168 million [1] - Following the acquisition, LSV Asset Management's total shareholding rose to 13.2692 million shares, increasing its ownership percentage from 5.98% to 6.03% [1]

Core Insights - Guangdong is intensifying its focus on the biopharmaceutical industry, leveraging policy benefits and innovation, but still faces deep-seated bottlenecks in R&D, commercialization, market access, and internationalization [1] Group 1: Innovation Mechanisms - The biopharmaceutical R&D process is characterized by high investment, long cycles, and significant risks, necessitating a more inclusive and precise innovation mechanism [1] - A typical original drug takes an average of 12 years from compound selection to market, with R&D costs exceeding $2 billion and a clinical trial failure rate of 90%, highlighting the need for a fault-tolerant mechanism [1] - Establishing a fault-tolerant mechanism could effectively encourage pharmaceutical companies to explore and innovate while maintaining stable growth [1] Group 2: Financial Support and Risk Compensation - A proposal for a provincial biopharmaceutical innovation risk compensation fund aims to provide subsidies for failed R&D projects and support companies purchasing clinical trial insurance [2] - Encouragement for banks to offer credit support to companies with fault-tolerant records and to pilot asset securitization for fault-tolerant projects in Guangzhou and Shenzhen [2] Group 3: Technology and Industry Integration - Emphasis on creating a source of original innovation by leveraging national laboratories and addressing major disease prevention and core technology needs [2] - Increased support for AI-driven innovative drug projects and precise funding for the discovery of original drugs to enhance the global competitiveness of Guangdong's pharmaceutical companies [2] Group 4: Market Access and Internationalization - The importance of market access and internationalization for high-quality industry development is highlighted, with suggestions to utilize the Guangdong-Hong Kong-Macao Greater Bay Area to enhance internationalization levels of pharmaceutical companies [2] - Recommendations to establish a GLP platform recognized internationally to support local pharmaceutical companies in Hong Kong and Macao [2] Group 5: Regulatory and Legal Framework - Proposal to include the Hengqin Guangdong-Macao Deep Cooperation Zone in the "Healthy China" pilot area, allowing for the use of drugs and medical devices already approved in Hong Kong and Macao [3] - Suggestions for establishing a collaborative mechanism for international trademark disputes, integrating resources from various departments to support companies in legal matters [3]

Group 1 - Guangzhou aims to develop the low-altitude economy by establishing vertical take-off and landing points at iconic locations such as the Canton Tower and Baiyun Mountain, promoting the "Aerial View Guangzhou" product to enhance urban life and economic development [1] - The city plans to create a comprehensive airspace system that includes applications for air transportation, low-altitude logistics, cultural tourism experiences, and emergency rescue, focusing on iterative upgrades and regular commercial operations [1] - Artificial intelligence and low-altitude economy are recognized as strategic emerging industries in China's national layout and are included in Guangzhou's "12218" modernization industrial system [1] Group 2 - Guangzhou will implement the "AI+" initiative to cultivate "AI + industry" solution companies and establish a comprehensive AI space platform, including empowerment centers and high-value parks [2] - The city plans to launch a series of major platforms, such as the aerospace intelligent manufacturing base and the low-altitude comprehensive hub project in the Guangdong-Hong Kong-Macao Greater Bay Area, to promote industrial clustering and development [2] - Investment funds for the AI and aerospace industries have been established to enhance the effectiveness of investment across the entire lifecycle and industry system, creating a multi-level investment fund matrix [2] Group 3 - New local regulations will be introduced to promote the development of artificial intelligence and low-altitude economy, providing targeted support for enterprises at different scales and development stages in areas such as project layout, scene opening, talent introduction, financing support, and market expansion [3]

Core Viewpoint - Guangzhou is set to introduce local regulations to promote artificial intelligence and low-altitude economy, along with various supportive policies for enterprises at different stages of development [1] Group 1: Policy Initiatives - The city will implement regulations for artificial intelligence development and low-altitude economy [1] - A series of policies will be introduced, including AI + industry application plans and low-altitude flight infrastructure planning [1] - Support will be categorized based on enterprise size and development stage, focusing on project layout, scenario opening, talent introduction, financing support, and market expansion [1] Group 2: Infrastructure Development - Guangzhou aims to accelerate the construction of major platforms such as the Guangdong-Hong Kong-Macao Greater Bay Area Aerospace Manufacturing Base and Huangpu Aerospace Manufacturing Equipment Park [1] - The city will promote the development of a comprehensive low-altitude hub project in the Greater Bay Area [1] - Plans include building a world-class low-altitude industrial ecosystem that integrates flight testing, promotion, manufacturing, and certification [1] Group 3: Application Scenarios - The city will develop a comprehensive unmanned system for all-space scenarios, enhancing applications in air traffic, low-altitude logistics, cultural tourism experiences, and emergency rescue [1] - Focus will be on the commercialization of eVTOL business models, creating clusters such as flight camps [1] - Iconic locations like Guangzhou Tower and Baiyun Mountain will feature vertical take-off and landing points, launching products like "Aerial View of Guangzhou" to integrate low-altitude economy into daily life and economic development [1]

适时应用大数据、AI等技术，探索与市场化匹配的估值机制 生物医药是新一轮科技革命和产业变革的前沿方向，更是广东在"十五五"开局之年，锚定发展新质生产 力、塑造未来竞争力的战略重点之一。近年来，为促进广东生物医药产业高质量发展，进一步推动生物 医药产业集聚成势，省市相继出台多项措施和行动方案，力争到2027年，全省生物医药与健康产业集群 规模超万亿元，规上医药工业规模超5000亿元。 广东两会进行中。1月27日，南都湾财社记者从广药集团获悉，今年广东省两会，广东省人大代表、广 药集团党委书记、董事长李小军多项建议聚焦为生物医药产业"松绑"，从而有效激发产业的新质生产 力。 对于医药科研创新管线类项目的评估，李小军建议创新应用大数据、AI等技术，探索与市场化匹配的 估值机制。同时，松绑引才机制，在全球多地设立离岸引才工作站。结合药物研发"九死一生"特性，李 小军还建议，从省级层面建立起针对生物医药产业全链条的系统性容错机制，按企业发展阶段设置容亏 梯度，"通过建立容错机制，破除创新障碍，有效激励医药企业勇于探索、积极尝试。" 创新评估机制 当前，生物医药产业的竞争已从资本与规模的比拼，转向顶尖人才与原始创新能力的 ...

Core Viewpoint - The A-share pharmaceutical sector has gained renewed investor interest due to the resurgence of COVID-19 cases in India, leading to fluctuations in the Chinese medicine ETF (560080) and notable stock performance among key companies in the sector [1][6]. Group 1: Market Performance - The Chinese medicine ETF (560080) experienced a nearly 2% decline on January 27, following a more than 1.4% increase the previous day, with trading volume surpassing 85 million yuan [1]. - Notable declines were observed in key stocks within the ETF, including Zhongsheng Pharmaceutical down over 7% and Yiling Pharmaceutical down over 5%, with several others also experiencing declines [3]. Group 2: Valuation Insights - The latest price-to-earnings ratio (PE TTM) for the index tracked by the Chinese medicine ETF (560080) is 24.57, indicating that the valuation is below 81.27% of the time since the index was published in May 2015, suggesting a favorable valuation opportunity [4]. Group 3: Company News - Zhongsheng Pharmaceutical announced a projected net profit of 260 million to 310 million yuan for 2025, marking a significant turnaround with an increase of 186.91% to 203.62% year-on-year [7]. - Yiling Pharmaceutical also forecasted a net profit of 1.2 billion to 1.3 billion yuan for 2025, indicating a key operational turning point [7]. - Kangyuan Pharmaceutical received approval for clinical trials of a new traditional Chinese medicine aimed at treating children's adenoid hypertrophy, marking a step forward in innovation [7]. Group 4: Industry Trends - The Chinese traditional medicine market is projected to exceed 700 billion yuan in 2024, driven by stable demand amid an aging population, although pricing volatility has been influenced by inventory adjustments and procurement policies [8]. - The industry is experiencing a consolidation trend, with leading companies capturing over half of the market revenue and profits, while ongoing policy focus on innovation and quality development is reshaping the competitive landscape [8].

Group 1 - The core point of the article highlights that on January 22, Baiyunshan executed a block trade of 150,000 shares, amounting to 3.6 million yuan, which represented 1.75% of the total trading volume for that day [1] - The transaction price was set at 24 yuan, reflecting a discount of 4.91% compared to the market closing price of 25.24 yuan [1] - The buying brokerage involved in the transaction was Minsheng Securities, while the selling brokerage was Zhongtai Securities [2]

Group 1 - The core incident involves a tourist stepping on a non-toothed hunting trap while hiking near Baiyun Mountain, resulting in minor discomfort but no serious injury [1] - Baiyun Mountain Scenic Area has initiated a thorough inspection of the affected area and surrounding regions, finding no similar traps so far [1][3] - The scenic area has reported the incident to the police, who are currently investigating the matter [3] Group 2 - Baiyun Mountain is classified as a nature reserve and is a no-hunting zone, making the use of hunting traps illegal [3] - The scenic area plans to enhance patrols in remote areas and improve its rapid response mechanism in collaboration with law enforcement and wildlife protection agencies [3] - The scenic area urges visitors to adhere to designated areas for sightseeing and to refrain from hunting wildlife or damaging vegetation, emphasizing the importance of protecting the ecological resources of Baiyun Mountain [3]